3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder

Journal of Psychiatry and Neuroscience

Volumn 34, Issue 4, 2009, Pages 263-271

  Andreazza, Ana Cristina ^a,b   Kapczinski, Flavio ^c   Kauer Sant'Anna, Marcia ^a,c   Walz, Julio C ^c   Bond, David J ^a   Gonçalves, Carlos A ^b   Young, L Trevor ^a   Yatham, Lakshmi N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ANTIDEPRESSANT AGENT; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; MOOD STABILIZER; NEUROLEPTIC AGENT; 3-NITROTYROSINE; ANTIOXIDANT; DRUG DERIVATIVE; PSYCHOTROPIC AGENT; TYROSINE;

ADULT; ARTICLE; BIPOLAR DISORDER; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; YOUNG MANIA RATING SCALE; BLOOD; DRUG EFFECT; METABOLISM; PROTEIN CARBONYLATION;

ADULT; ANTIOXIDANTS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; FEMALE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PSYCHOTROPIC DRUGS; TYROSINE;

EID: 70149115047     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Belmaker RH. Medical progress: bipolar disorder. N Engl J Med 2004;351:476-486
2. Sajatovic M. Bipolar disorder: disease burden. Am J Manag Care 2005;11(Suppl):S80-4.
3. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA 2005;293:2528-2530
4. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64:543-552 (Pubitemid 46718287)
5. McIntyre RS, Konarski JZ, Soczynska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv 2006;57:1140-1144
6. Halliwell B. Oxidative stress and neurodegeneration: Where are we now? J Neurochem 2006;97:1634-1658 (Pubitemid 43873658)
7. Sies H. Oxidative stress: from basic research to clinical application. Am J Med 1991;91(3C):31S-8S.
8. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001;18:685-716. (Pubitemid 32948277)
9. Takuma K, Baba A, Matsuda T. Astrocyte apoptosis: implications for neuroprotection. Prog Neurobiol 2004;72:111-127
10. Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem 2003;384:505-516
11. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978;14:633-643
12. Baez S, Segura-Aguilar J, Widersten M, et al. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 1997;324:25-28
13. Stokes AH, Hastings TG, Vrana KE. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999;55(6):659-665
14. Obata T. Dopamine efflux by MPTP and hydroxyl radical generation. J Neural Transm 2002;109:1159-1180 (Pubitemid 35013715)
15. Beal MF. Oxidatively modified proteins in aging and disease. Free Radic Biol Med 2002;32:797-803. (Pubitemid 34439250)
16. Berlett BS, Levine RL, Stadtman ER. Carbon dioxide stimulates peroxynitrite-mediated nitration of tyrosine residues and inhibits oxidation of methionine residues of glutamine synthetase: both modifications mimic effects of adenylylation. Proc Natl Acad Sci U S A 1998;95:2784-2789
17. Ji Y, Bennett BM. Activation of microsomal glutathione S-transferase by peroxynitrite. Mol Pharmacol 2003;63:136-146 (Pubitemid 36043817)
18. Abdalla DS, Monteiro HP, Oliveira JA, et al. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem 1986;32:805-807 (Pubitemid 17028354)
19. Kuloglu M, Ustundag B, Atmaca M, et al. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002;20:171-175
20. Andreazza AC, Cassini C, Rosa AR, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007;41:523-529 (Pubitemid 46227446)
21. Machado-Vieira R, Andreazza AC, Viale CI, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007;421:33-36 (Pubitemid 46908861)
22. Savas HA, Herken H, Yürekli M, et al. Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology 2002;45:57-61. (Pubitemid 34224978)
23. Savas HA, Gergerlioglu HS, Armutcu F. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry 2006;7:51-55
24. Selek S, Savas HA, Gergerlioglu HS, et al. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 2008;107:89-94. (Pubitemid 351288914)
25. Andreazza AC, Noronha Frey B, Erdtmann B, et al. DNA damage in bipolar disorder. Psychiatry Res 2007;153:27-32.
26. Buttner N, Bhattacharyya S, Walsh J, et al. DNA fragmentation is increased in non-GABAergic neurons in bipolar disorder but not in schizophrenia. Schizophr Res 2007;93:33-41. (Pubitemid 46817926)
27. Naydenov AV, MacDonald ML, Ongur D, et al. Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. Arch Gen Psychiatry 2007;64:555-564 (Pubitemid 46718288)
28. Berk M, Copolov DL, Dean O, et al. N-acetylcysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64:468-475
29. Schuepbach D, Novick D, Haro JM, et al.; EMBLEM Advisory Board. Determinants of voluntary vs. involuntary admission in bipolar disorder and the impact of adherence. Pharmacopsychiatry 2008;41:29-36.
30. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990;47:1106-1111
31. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989;321:1489-1493
32. Swann AC, Bowden CL, Calabrese JR, et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999;156:1264-1266
33. Berk M, Conus P, Lucas N, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord 2007;9:671-678 (Pubitemid 350042401)
34. Yanik M, Vural H, Tutkun H, et al. The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci 2004;254:43-47 (Pubitemid 39310548)
35. Savas HA, Gergerlioglu HS, Gurel A, et al. Increased xanthine oxidase and malondialdehyde levels in euthymic bipolar patients. Klinik Psikiyatri Dergisi 2005;8:180-185
36. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian network for mood and anxiety treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005;7 Suppl 3:5-69.
37. Yatham LN, Kennedy SH, O'Donovan C, et al. Guidelines Group. Canadian network for mood and anxiety treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006;8:721-739
38. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York (NY): Biometrics Research, New York State Psychiatric Institute; 2002.
39. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978;133:429-435 (Pubitemid 9006756)
40. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
41. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: The Association; 1994.
42. Khan J, Brennand DM, Bradley N, et al. 3-Nitrotyrosine in the proteins of human plasma determined by an ELISA method. Biochem J 1998;332:807-808
43. Davis IC, Zajac AJ, Nolte KB, et al. Elevated generation of reactive oxygen/nitrogen species in hantavirus cardiopulmonary syndrome. J Virol 2002;76:8347-8359
44. Ckless K, Lampert A, Reiss J, et al. Inhibition of arginase activity enhances inflammation in mice with allergic airway disease, in association with increases in protein S-nitrosylation and tyrosine nitration. J Immunol 2008;181:4255-4264
45. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2008;12:447-458
46. Berk M, Malhi GS, Hallam K, et al. Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives. J Affect Disord 2009;114:1-13.
47. Schimmelmann BG, Huber CG, Lambert M, et al. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 2008;42:982-990
48. Wang JF, Azzam JE, Young LT. Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 2003;116:485-489
49. Yatham LN. Translating knowledge of genetics and pharmacology into improving everyday practice. Bipolar Disord 2005;7(Suppl 4):13-20.
50. Berk M, Dodd S, Kauer-Sant'Anna M, et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 2007;(434):41-49
51. Rees JN, Florang VR, Anderson DG, et al. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate. Chem Res Toxicol 2007;20:1536-1542
52. Chen L, Ding Y, Cagniard B, et al. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 2008;28:425-433
53. Maker HS, Weiss C, Silides DJ, et al. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem 1981;36:589-593 (Pubitemid 11190630)
54. Berman SB, Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 1999;73:1127-1137
55. Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A 1996;93:1956-1961
56. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88.
57. Tirmenstein MA, Hu CX, Scicchitano MS, et al. Effects of 6-hydroxydopamine on mitochondrial function and glutathione status in SH-SY5Y human neuroblastoma cells. Toxicol In Vitro 2005;19:471-479 (Pubitemid 40501713)
58. Yildiz-Yesiloglu A, Ankerst DP. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res 2006;147:1-25. (Pubitemid 44067434)
59. Gergerlioglu HS, Savas HA, Bulbul F, et al. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:697-702. (Pubitemid 46467046)
60. Kato T. Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium 2008;44:92-102.
61. Ischiropoulos H. Biological selectivity and functional aspects of protein tyrosine nitration. Biochem Biophys Res Commun 2003;305:776-783 (Pubitemid 36581936)
62. Ara J, Przedborski S, Naini AB, et al. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc Natl Acad Sci U S A 1998;95:7659-7663 (Pubitemid 28293309)
63. MacMillan-Crow LA, Crow JP, Thompson JA. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry 1998;37:1613-1622
64. Lee C-I, Liu X, Zweier J. Regulation of xanthine oxidase by nitric oxide and peroxynitrite. J Biol Chem 2000;275:9369-9376 (Pubitemid 30185161)
65. Crow JP, Ischiropoulos H. Detection and quantitation of nitrotyrosine residues in proteins: in vivo marker of peroxynitrite. Methods Enzymol 1996;269:185-194 (Pubitemid 26295707)
66. Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2000;2:180-190
67. Konradi C, Eaton M, MacDonald ML, et al. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004;61:300-308 (Pubitemid 38295832)
68. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 2005;14:241-253
69. Sun X, Wang JF, Tseng M, et al. Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci 2006;31:189-196 (Pubitemid 43954738)
70. Benes FM, Matzilevich D, Burke RE, et al. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol Psychiatry 2006;11:241-251 (Pubitemid 43316055)
71. Ma TC, Mihm MJ, Bauer JA, et al. Bioenergetic and oxidative effects of free 3-nitrotyrosine in culture: selective vulnerability of dopaminergic neurons and increased sensitivity of non-dopaminergic neurons to dopamine oxidation. J Neurochem 2007;103:131-144
72. Ferger B, Themann C, Rose S, et al. 6-hydroxydopamine increases the hydroxylation and nitration of phenylalanine in vivo: implication of peroxynitrite formation. J Neurochem 2001;78:509-514 (Pubitemid 32729978)
73. Wang JF, Shao L, Sun X, et al. Glutathione S-transferase is a novel target for mood stabilizing drugs in primary cultured neurons. J Neurochem 2004;88:1477-1484 (Pubitemid 38366924)
74. Frey BN, Valvassori SS, Réus GZ, et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006;31:326-332
75. Schmidt AJ, Heiser P, Hemmeter UM, et al. Effects of antidepressants on mRNA levels of antioxidant enzymes in human monocytic U-937 cells. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1567-1573
76. Lieberman JA, Perkins DO, Jarskog LF. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spectr 2007;12 (3 Suppl 4):1-13.